These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32386595)

  • 1. Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1.
    Hu Z; Rolt A; Hu X; Ma CD; Le DJ; Park SB; Houghton M; Southall N; Anderson DE; Talley DC; Lloyd JR; Marugan JC; Liang TJ
    Cell Chem Biol; 2020 Jul; 27(7):780-792.e5. PubMed ID: 32386595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner.
    Lee M; Yang J; Jo E; Lee JY; Kim HY; Bartenschlager R; Shin EC; Bae YS; Windisch MP
    Sci Rep; 2017 Mar; 7():44676. PubMed ID: 28333153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
    Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
    J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.
    He S; Lin B; Chu V; Hu Z; Hu X; Xiao J; Wang AQ; Schweitzer CJ; Li Q; Imamura M; Hiraga N; Southall N; Ferrer M; Zheng W; Chayama K; Marugan JJ; Liang TJ
    Sci Transl Med; 2015 Apr; 7(282):282ra49. PubMed ID: 25855495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein.
    Hung TC; Jassey A; Liu CH; Lin CJ; Lin CC; Wong SH; Wang JY; Yen MH; Lin LT
    Phytomedicine; 2019 Feb; 53():62-69. PubMed ID: 30668413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuralized E3 Ubiquitin Protein Ligase 3 Is an Inducible Antiviral Effector That Inhibits Hepatitis C Virus Assembly by Targeting Viral E1 Glycoprotein.
    Zhao Y; Cao X; Guo M; Wang X; Yu T; Ye L; Han L; Hei L; Tao W; Tong Y; Xu Y; Zhong J
    J Virol; 2018 Nov; 92(21):. PubMed ID: 30111563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors.
    Banda DH; Perin PM; Brown RJP; Todt D; Solodenko W; Hoffmeyer P; Kumar Sahu K; Houghton M; Meuleman P; Müller R; Kirschning A; Pietschmann T
    J Hepatol; 2019 Jun; 70(6):1082-1092. PubMed ID: 30769006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain.
    Moustafa RI; Haddad JG; Linna L; Hanoulle X; Descamps V; Mesalam AA; Baumert TF; Duverlie G; Meuleman P; Dubuisson J; Lavie M
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30068644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2.
    Yin P; Zhang L; Ye F; Deng Y; Lu S; Li YP; Zhang L; Tan W
    Sci Rep; 2017 Jun; 7(1):3976. PubMed ID: 28638089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry.
    Liu R; Tewari M; Kong R; Zhang R; Ingravallo P; Ralston R
    Antiviral Res; 2010 May; 86(2):172-9. PubMed ID: 20156485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Analysis of Hepatitis C Virus (HCV) Envelope Protein E1 Using a
    Tong Y; Chi X; Yang W; Zhong J
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28100619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.
    Haddad JG; Rouillé Y; Hanoulle X; Descamps V; Hamze M; Dabboussi F; Baumert TF; Duverlie G; Lavie M; Dubuisson J
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain.
    Chi X; Niu Y; Cheng M; Liu X; Feng Y; Zheng F; Fan J; Li X; Jin Q; Zhong J; Li YP; Yang W
    Sci Rep; 2016 Apr; 6():25224. PubMed ID: 27121372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational analysis of the hepatitis C virus E1 glycoprotein in retroviral pseudoparticles and cell-culture-derived H77/JFH1 chimeric infectious virus particles.
    Russell RS; Kawaguchi K; Meunier JC; Takikawa S; Faulk K; Bukh J; Purcell RH; Emerson SU
    J Viral Hepat; 2009 Sep; 16(9):621-32. PubMed ID: 19302336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion.
    Ma CD; Imamura M; Talley DC; Rolt A; Xu X; Wang AQ; Le D; Uchida T; Osawa M; Teraoka Y; Li K; Hu X; Park SB; Chalasani N; Irvin PH; Dulcey AE; Southall N; Marugan JJ; Hu Z; Chayama K; Frankowski KJ; Liang TJ
    Nat Microbiol; 2020 Dec; 5(12):1532-1541. PubMed ID: 32868923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel small molecule inhibitor of hepatitis C virus entry.
    Baldick CJ; Wichroski MJ; Pendri A; Walsh AW; Fang J; Mazzucco CE; Pokornowski KA; Rose RE; Eggers BJ; Hsu M; Zhai W; Zhai G; Gerritz SW; Poss MA; Meanwell NA; Cockett MI; Tenney DJ
    PLoS Pathog; 2010 Sep; 6(9):e1001086. PubMed ID: 20838466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.
    Al Olaby RR; Cocquerel L; Zemla A; Saas L; Dubuisson J; Vielmetter J; Marcotrigiano J; Khan AG; Vences Catalan F; Perryman AL; Freundlich JS; Forli S; Levy S; Balhorn R; Azzazy HM
    PLoS One; 2014; 9(10):e111333. PubMed ID: 25357246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry.
    Douam F; Dao Thi VL; Maurin G; Fresquet J; Mompelat D; Zeisel MB; Baumert TF; Cosset FL; Lavillette D
    Hepatology; 2014 Mar; 59(3):776-88. PubMed ID: 24038151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of hepatitis B and C virus envelope glycoproteins.
    Jeulin H; Velay A; Murray J; Schvoerer E
    World J Gastroenterol; 2013 Feb; 19(5):654-64. PubMed ID: 23429668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conservation of hydrophobicity within viral envelope glycoproteins reveals a putative hepatitis C virus fusion peptide.
    Taylor A; O'Leary JM; Pollock S; Zitzmann N
    Protein Pept Lett; 2009; 16(7):815-22. PubMed ID: 19601912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.